Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.54 |
| ▸ | GRIK1 | P39086 | 4/20 | 0.50 |
| ▸ | GRIA2 | P42262 | 4/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.45 |
| ▸ | HRH1 | P35367 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.43 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.43 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13584955 | 1.00 | HRH3 (0.54) | HRH3GRIK1GRIA2SLC6A4SLC6A2 | |
| SCHEMBL29380816 | 1.00 | HRH3 (0.54) | HRH3GRIK1GRIA2SLC6A4SLC6A2 | |
| SCHEMBL3448485 | 1.00 | HRH3 (0.54) | HRH3GRIK1GRIA2SLC6A4SLC6A2 | |
| SCHEMBL3448482 | 1.00 | HRH3 (0.54) | HRH3GRIK1GRIA2SLC6A4SLC6A2 | |
| SCHEMBL3180028 | 1.00 | HRH3 (0.54) | HRH3GRIK1GRIA2SLC6A4SLC6A2 | |
| Hydrochloric Acid SCHEMBL25363703 | 0.98 | HRH3 (0.53) | HRH3GRIK1GRIA2SLC6A4SLC6A2 | |
| SCHEMBL3180040 | 0.91 | GRIK1 (0.49) | HRH3GRIK1GRIA2 | |
| SCHEMBL11249221 | 0.91 | GRIK1 (0.49) | HRH3GRIK1GRIA2 | |
| Proline SCHEMBL3459060 | 0.89 | HRH3 (0.55) | HRH3GRIK1GRIA2 | |
| SCHEMBL464484 | 0.87 | HRH3 (0.52) | HRH3GRIK1GRIA2SLC6A4SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4628592-A1 | PEPTIDE PRODUCTION METHOD COMPRISING STEP FOR TRANSLATING AMINO ACID HAVING OXYGEN ATOM AT SPECIFIC POSITION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-10-08 | — | — | EP | disclosed |
| WO-2024128195-A1 | PEPTIDE PRODUCTION METHOD COMPRISING STEP FOR TRANSLATING AMINO ACID HAVING OXYGEN ATOM AT SPECIFIC POSITION | 中外製薬株式会社 | 2024-06-20 | — | — | WO | disclosed |
| WO-2024118635-A2 | THERMOSTABLE BINDING SCAFFOLDS | NECTAGEN, INC. (US) | 2024-06-06 | — | — | WO | disclosed |
| US-20240174730-A1 | VARIANT FC DOMAINS AND USES THEREOF | CIDARA THERAPEUTICS, INC. | 2024-05-30 | — | — | US | disclosed |
| US-20240156975-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS | CIDARA THERAPEUTICS, INC. | 2024-05-16 | — | — | US | disclosed |
| US-11873291-B2 | Quinoline cGAS antagonist compounds | IMMUNESENSOR THERAPEUTICS, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| US-11873291-B2 | Quinoline cGAS antagonist compounds | IMMUNESENSOR THERAPEUTICS, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| WO-2024010810-A2 | FC CONJUGATES INCLUDING AN INHIBITOR OF CD73 AND USES THEREOF | CIDARA THERAPEUTICS, INC. (US) | 2024-01-11 | — | — | WO | disclosed |
| EP-4297796-A1 | VARIANT FC DOMAINS AND USES THEREOF | CIDARA THERAPEUTICS, INC. (US) | 2024-01-03 | — | — | EP | disclosed |
| US-20230398226-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS | CIDARA THERAPEUTICS, INC. | 2023-12-14 | — | — | US | disclosed |
| WO-2015112333-A1 | LABELED MOLECULAR AGENTS FOR IMAGING CYSTINE/GLUTAMATE ANTI PORTER | GENERAL ELECTRIC COMPANY (US) | 2015-07-30 | — | — | WO | disclosed |
| US-20150202333-A1 | LABELED MOLECULAR IMAGING AGENTS AND METHODS OF USE | GENERAL ELECTRIC COMPANY (US) | 2015-07-23 | — | — | US | disclosed |
| US-20150202333-A1 | LABELED MOLECULAR IMAGING AGENTS AND METHODS OF USE | GENERAL ELECTRIC COMPANY (US) | 2015-07-23 | — | — | US | disclosed |
| WO-2015035102-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF FUNGAL INFECTIONS | CIDARA THERAPEUTICS, INC. (US) | 2015-03-12 | — | — | WO | disclosed |
| US-20130225506-A1 | TEMPLATE-FIXED PEPTIDOMIMETICS WITH CXCR7 MODULATING ACTIVITY | POLYPHOR AG (CH) | 2013-08-29 | — | — | US | disclosed |
| EP-1155013-B1 | HETEROCYCLIC BENZENESULPHONAMIDE COMPOUNDS AS BRADYKININE ANTAGONISTS | FOURNIER IND & SANTE (FR) | 2003-07-23 | — | — | EP | disclosed |
| US-6479515-B1 | FOR THE TREATMENT OF PAIN AND INFLAMMATION, AND ESPECIALLY IN THE TREATMENT OF ASTHMA, CEREBRAL TRAUMATIC SHOCK AND ALLERGIC RHINITIS | FOURNIER INDUSTRIE ET SANTE (FR) | 2002-11-12 | — | — | US | disclosed |
| EP-1155013-A1 | HETEROCYCLIC BENZENESULPHONAMIDE COMPOUNDS AS BRADYKININE ANTAGONISTS | FOURNIER INDUSTRIE ET SANTE (FR) | 2001-11-21 | — | — | EP | disclosed |
| WO-2000050418-A9 | HETEROCYCLIC BENZENESULPHONAMIDE COMPOUNDS AS BRADYKININE ANTAGONISTS | FOURNIER IND & SANTE (FR) | 2001-02-22 | — | — | WO | disclosed |
| WO-2000050418-A1 | HETEROCYCLIC BENZENESULPHONAMIDE COMPOUNDS AS BRADYKININE ANTAGONISTS | FOURNIER INDUSTRIE ET SANTE (FR) | 2000-08-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230398226-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS | FCGR3B, ALB, FCGR1A | HRH3 614/4885GRIK1 4259/4885GRIA2 4007/4885 |
| US-11873291-B2 | Quinoline cGAS antagonist compounds | CGAS, GLS2, GLS | HRH3 994/4885GRIK1 936/4885GRIA2 445/4885 |
| US-20150202333-A1 | LABELED MOLECULAR IMAGING AGENTS AND METHODS OF USE | SLC7A11, GLS, SLC3A2 | HRH3 2557/4885GRIK1 301/4885GRIA2 302/4885 |
| US-20130225506-A1 | TEMPLATE-FIXED PEPTIDOMIMETICS WITH CXCR7 MODULATING ACTIVITY | CXCR1, CXCL12, CXCR6 | HRH3 163/4885GRIK1 2104/4885GRIA2 599/4885 |
| US-20240174730-A1 | VARIANT FC DOMAINS AND USES THEREOF | FCGR3B, FCGRT, FCGR2A | HRH3 3810/4885GRIK1 2763/4885GRIA2 2231/4885 |
| US-20240156975-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS | FCGR3B, ALB, FCGR1A | HRH3 614/4885GRIK1 4259/4885GRIA2 4007/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.